# Lenvatinib and Pembrolizumab in Resectable Mucosal Melanoma

> **NCT04622566** · PHASE2 · UNKNOWN · sponsor: **Peking University Cancer Hospital & Institute** · enrollment: 26 (estimated)

## Conditions studied

- Mucosal Melanoma
- Neoadjuvant Treatment

## Interventions

- **DRUG:** Lenvatinib, Pembrolizumab

## Key facts

- **NCT ID:** NCT04622566
- **Lead sponsor:** Peking University Cancer Hospital & Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-12-30
- **Primary completion:** 2021-12-30
- **Final completion:** 2023-12-30
- **Target enrollment:** 26 (ESTIMATED)
- **Last updated:** 2020-11-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04622566

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04622566, "Lenvatinib and Pembrolizumab in Resectable Mucosal Melanoma". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT04622566. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*